Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randy Jensen

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Cell Reports|October 27, 2016
MEK Inhibitors Reverse Growth of Embryonal Brain Tumors Derived from Oligoneural Precursor CellsKatarzyna Modzelewska, Elena F Boer, Timothy L Mosbruger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Bevacizumab alone and in combination with irinotecan in recurrent glioblastomaHenry S Friedman, Michael D Prados, Patrick Y Wen, et al.
The Oncologist|December 15, 2010
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN studyJames J Vredenburgh, Timothy Cloughesy, Meghna Samant, et al.
Neuro-Oncology|November 19, 2010
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumabMichael Prados, Timothy Cloughesy, Meghna Samant, et al.
Neuro-Oncology|May 12, 2011
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumabJeffrey S Wefel, Timothy Cloughesy, James L Zazzali, et al.
JCI Insight|September 20, 2019
Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNKAmber J Giles, Shuyu Hao, Michelle Padget, et al.
Neuro-Oncology|January 15, 2015
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III studyJames Schuster, Rose K Lai, Lawrence D Recht, et al.
Neuro-Oncology|April 29, 2017
Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patientsJavier M Figueroa, Johan Skog, Johnny Akers, et al.
Acta Neurochirurgica|April 6, 2026
The Ki-67 proliferation index and recurrence risk of intracranial meningioma: a multicenter, retrospective cohort study of 5,050 patientsChristian Mirian, Lasse Rehné Jensen, Tareq A Juratli, et al.
Journal of Neuro-Oncology|February 9, 2024
The importance of considering competing risks in recurrence analysis of intracranial meningiomaChristian Mirian, Lasse Rehné Jensen, Tareq A Juratli, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Cell Reports|October 27, 2016
MEK Inhibitors Reverse Growth of Embryonal Brain Tumors Derived from Oligoneural Precursor CellsKatarzyna Modzelewska, Elena F Boer, Timothy L Mosbruger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Bevacizumab alone and in combination with irinotecan in recurrent glioblastomaHenry S Friedman, Michael D Prados, Patrick Y Wen, et al.
The Oncologist|December 15, 2010
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN studyJames J Vredenburgh, Timothy Cloughesy, Meghna Samant, et al.
Neuro-Oncology|November 19, 2010
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumabMichael Prados, Timothy Cloughesy, Meghna Samant, et al.
Neuro-Oncology|May 12, 2011
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumabJeffrey S Wefel, Timothy Cloughesy, James L Zazzali, et al.
JCI Insight|September 20, 2019
Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNKAmber J Giles, Shuyu Hao, Michelle Padget, et al.
Neuro-Oncology|January 15, 2015
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III studyJames Schuster, Rose K Lai, Lawrence D Recht, et al.
Neuro-Oncology|April 29, 2017
Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patientsJavier M Figueroa, Johan Skog, Johnny Akers, et al.
Acta Neurochirurgica|April 6, 2026
The Ki-67 proliferation index and recurrence risk of intracranial meningioma: a multicenter, retrospective cohort study of 5,050 patientsChristian Mirian, Lasse Rehné Jensen, Tareq A Juratli, et al.
Journal of Neuro-Oncology|February 9, 2024
The importance of considering competing risks in recurrence analysis of intracranial meningiomaChristian Mirian, Lasse Rehné Jensen, Tareq A Juratli, et al.
Pageof 5